Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

First Tracks Biotherapeutics, Inc.

NASDAQ: TRAX · Life Sciences · 5 alerts · CIK 2091349

First Tracks Biotherapeutics, Inc. stories on ALFA USA NewsRead the news →
Share price
$46.56Close, Nov 16
Market cap
$1.96B
Shares outstanding
42.02MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All First Tracks Biotherapeutics, Inc. filings on SEC EDGAR ↗

4:24 PM ET 10-Q
Financial Results

First Tracks Biotherapeutics Q3 2026 Results: Net Loss of $31.4M, Loss Narrows

First Tracks Biotherapeutics completed its spin-off from AnaptysBio on April 20, 2026, and began trading under the symbol TRAX. For the nine months ended September 30, 2026, the company reported a net loss of $115.2 million, driven by $83.4 million in research and development expenses for its clinical-stage antibody therapies.

Key figure
Net loss $31.4M
4:19 PM ET 8-K
Financial Results

First Tracks Biotherapeutics Financial Results

First Tracks Biotherapeutics reported Q3 2026 financial results, highlighting a pro forma cash position of $343 million following a $200 million private placement. The company reported positive Phase 1b data for its lead candidate ANB033 in celiac disease and plans to initiate late-stage clinical development in 2027.

“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet.”

Daniel Faga, president and chief executive officer
4:06 PM ET 8-K
Capital Raise

First Tracks Biotherapeutics Capital Raise

First Tracks Biotherapeutics, Inc. closed a private placement of 6,106,870 shares of common stock on October 19, 2026. In connection with the closing, the company entered into a registration rights agreement requiring it to file a resale registration statement for the investors within 30 days.

4:29 PM ET 8-K
Capital Raise

First Tracks Biotherapeutics Capital Raise of $200M

First Tracks Biotherapeutics entered into a securities purchase agreement for a $200 million private placement (PIPE) of 6,106,870 shares of common stock at $32.75 per share. The offering includes participation from several institutional investors and is intended to fund the clinical development of ANB033 and other general corporate purposes.

Value
$200M
Counterparty
Affinity Asset Advisors, LLC, First Light Asset Management, Sirenia Capital Management LP, TCGX, Trails Edge Capital Partners, Vestal Point Capital
8:33 AM ET 8-K
Clinical Trial Data

First Tracks Biotherapeutics Clinical Trial Data

First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.